Related Experiment Videos
A placebo-controlled trial of isoprinosine in patients with multiple sclerosis
N M Milligan1, D H Miller, D A Compston
1Department of Neurology, University Hospital of Wales, Heath Park, Cardiff, UK.
Abstract:
Isoprinosine was used under double-blind, randomised, and placebo-controlled conditions in 52 patients with relapsing/remitting or progressive multiple sclerosis. All patients received pulsed treatment with methylprednisolone. There was no significant effect of treatment on clinical disability or the accumulation of MRI abnormalities, after correction of results for multiple comparisons. It is concluded that isoprinosine is not effective therapy for multiple sclerosis.
Insights
Isoprinosine did not improve clinical disability or MRI abnormalities in multiple sclerosis patients. This study found no significant benefit of isoprinosine when used alongside methylprednisolone for multiple sclerosis treatment.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
- Current treatments aim to reduce inflammation and manage symptoms, but effective disease-modifying therapies are continually sought.
- Isoprinosine, an immunomodulatory agent, has been investigated for various viral infections and immune conditions.
Purpose of the Study:
- To evaluate the efficacy of isoprinosine as a therapeutic agent in patients with multiple sclerosis.
- To assess the impact of isoprinosine on clinical disability progression and magnetic resonance imaging (MRI) abnormalities in MS.
Main Methods:
- A double-blind, randomized, placebo-controlled trial was conducted.
- Fifty-two patients with relapsing-remitting or progressive multiple sclerosis participated.
- All patients received pulsed methylprednisolone treatment in addition to either isoprinosine or a placebo.
Main Results:
- No statistically significant difference was observed in clinical disability scores between the isoprinosine and placebo groups.
- The accumulation of MRI-detected abnormalities did not differ significantly between the treatment arms.
- These findings remained consistent after adjusting for multiple comparisons.
Conclusions:
- Isoprinosine demonstrated no significant therapeutic effect in patients with multiple sclerosis under the studied conditions.
- The combination of isoprinosine with pulsed methylprednisolone is not an effective treatment strategy for multiple sclerosis.
- Further research may be warranted to explore other potential applications or formulations, but current evidence does not support its use for MS.